PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50123C00050 — VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOG…

VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOG… is a federal NONE award for Department of Health and Human Services (HHS) held by VENATORX PHARMACEUTICALS INC. Estimated value $39.8M ($39.8M obligated). Current period of performance ends Dec 31, 2027 (potential Dec 31, 2029). Last award drew 1 bidder.

$39.8M
Estimated Value
Dec 31, 2027
PoP End / Expires
1
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

VENATORX PHARMACEUTICALS INC holds $44.4M across 6 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Dec 31, 2027 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract number75A50123C00050
AgencyDepartment of Health and Human Services (HHS)
IncumbentVENATORX PHARMACEUTICALS INC
UEIMBBKNBU5DCC6
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN13
PoP end (current)Dec 31, 2027
PoP end (w/ options)Dec 31, 2029
Obligated$39.8M

VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS.

Recompete timing

Public
Expiring in 501 days

Current PoP ends Dec 31, 2027 (501 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Jul 1, 2026.

Watch this contract — one email →

Incumbent footprint

Public record

VENATORX PHARMACEUTICALS INC$44.4M obligated across 6 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$44.8M · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open VENATORX PHARMACEUTICALS INC’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75A50123C00050?

75A50123C00050 (VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOG…) is a Department of Health and Human Services (HHS) award with an estimated value of $39.8M, currently held by VENATORX PHARMACEUTICALS INC. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75A50123C00050?

VENATORX PHARMACEUTICALS INC is the incumbent with $44.4M across 6 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2027.

When does 75A50123C00050 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50123C00050